Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | LTB4R | Q15722 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | CNR2 | P34972 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL473576 | 1.00 | TSHR (0.68) | TSHRSMN1; SMN2KMT2AMEN1HTT | |
| SCHEMBL264775 | 1.00 | TSHR (0.68) | TSHRSMN1; SMN2KMT2AMEN1HTT | |
| SCHEMBL1073143 | 1.00 | TSHR (0.68) | TSHRSMN1; SMN2KMT2AMEN1HTT | |
| Phosphine SCHEMBL27480220 | 0.98 | TSHR (0.66) | TSHRSMN1; SMN2KMT2AMEN1HTT | |
| SCHEMBL27523343 | 0.90 | TSHR (0.57) | TSHRSMN1; SMN2KMT2AMEN1HTT | |
| SCHEMBL16486901 | 0.89 | MMP12 (0.58) | TSHR | |
| SCHEMBL15587062 | 0.88 | LTB4R (0.59) | TSHRSMN1; SMN2KMT2AHPGDLTB4R | |
| SCHEMBL3254192 | 0.88 | LTB4R (0.59) | TSHRSMN1; SMN2KMT2AHPGDLTB4R | |
| SCHEMBL8826605 | 0.88 | LTB4R (0.59) | TSHRSMN1; SMN2KMT2AHPGDLTB4R | |
| SCHEMBL5007804 | 0.88 | TSHR (0.55) | TSHRSMN1; SMN2KMT2AMEN1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2752419-B1 | SPIROBENZYLAMINE-PHOSPHINE, PREPARATION METHOD THEREFOR AND USE THEREOF | ZHEJIANG JIUZHOU PHARM CO LTD (CN) | 2019-01-02 | — | — | EP | disclosed |
| US-9828345-B2 | Phenylpyrazole derivatives as potent ROCK1 and ROCK2 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-11-28 | — | — | US | disclosed |
| US-20160002172-A1 | PHENYLPYRAZOLE DERIVATIVES AS POTENT ROCK1 AND ROCK2 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2016-01-07 | — | — | US | disclosed |
| US-9108995-B2 | Spirobenzylamine-phosphine, preparation method therefor and use thereof | ZHEJIANG JIUZHOU PHARMACEUTICAL CO., LTD. (CN) | 2015-08-18 | — | — | US | disclosed |
| US-9108995-B2 | Spirobenzylamine-phosphine, preparation method therefor and use thereof | ZHEJIANG JIUZHOU PHARMACEUTICAL CO., LTD. (CN) | 2015-08-18 | — | — | US | disclosed |
| EP-2272853-B1 | SPIRO PHOSPHORUS-OXAZOLINE, SYNTHESIS AND USE THEREOF | ZHEJIANG JIUZHOU PHARM CO LTD (CN) | 2014-08-27 | — | — | EP | disclosed |
| US-20140194638-A1 | Spirobenzylamine-Phosphine, Preparation Method Therefor And Use Thereof | ZHEJIANG JIUZHOU PHARMACEUTICAL CO., LTD. (CN) | 2014-07-10 | — | — | US | disclosed |
| US-20140194638-A1 | Spirobenzylamine-Phosphine, Preparation Method Therefor And Use Thereof | ZHEJIANG JIUZHOU PHARMACEUTICAL CO., LTD. (CN) | 2014-07-10 | — | — | US | disclosed |
| EP-2752419-A1 | SPIROBENZYLAMINE-PHOSPHINE, PREPARATION METHOD THEREFOR AND USE THEREOF | Zhejiang Jiuzhou Pharmaceutical Co., Ltd. (CN) | 2014-07-09 | — | — | EP | disclosed |
| US-8450493-B2 | Spiro phosphine-oxazoline, preparation method and application thereof | Zheijiang Jiuzhou Pharmaceutical Co., Ltd. (CN) | 2013-05-28 | — | — | US | disclosed |
| US-8450493-B2 | Spiro phosphine-oxazoline, preparation method and application thereof | Zheijiang Jiuzhou Pharmaceutical Co., Ltd. (CN) | 2013-05-28 | — | — | US | disclosed |
| US-20110118472-A1 | Spiro Phosphine-Oxazoline, Preparation Method and Application thereof | Zheijiang Jiuzhou Pharmaceutical Co., Ltd. (CN) | 2011-05-19 | — | — | US | disclosed |
| US-20110118472-A1 | Spiro Phosphine-Oxazoline, Preparation Method and Application thereof | Zheijiang Jiuzhou Pharmaceutical Co., Ltd. (CN) | 2011-05-19 | — | — | US | disclosed |
| EP-2272853-A1 | SPIRO PHOSPHORUS-OXAZOLINE, SYNTHESIS AND USE THEREOF | Zhejiang Jiuzhou Pharmaceutical Co., Ltd. (CN) | 2011-01-12 | — | — | EP | disclosed |
| US-7309721-B2 | Immunosuppressants for treating diseases and conditions of bone marrow, organ and tissue transplant rejection; chemotherapeutic drug for cancers; antiinflammatory agents for rheumatoid arthritis; activate the production of lymphocyte; 2-Amino-4-(4-(octylphenyl))butanol, O-phosphate | MERCK + CO., INC. (US) | 2007-12-18 | — | — | US | disclosed |
| WO-2007111994-A2 | COMPOUNDS AND METHODS FOR TREATMENT OF DISORDERS ASSOCIATED WITH ER STRESS | SYNDEXA PHARMACEUTICALS CORPORATION (US) | 2007-10-04 | — | — | WO | disclosed |
| US-20070224263-A1 | Aminoalkylphosphonates and related compounds as Edg receptor agonists | DOHERTY GEORGE A | 2007-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160002172-A1 | PHENYLPYRAZOLE DERIVATIVES AS POTENT ROCK1 AND ROCK2 INHIBITORS | ROCK1, ROCK2, MYLK | TSHR 3090/4885SMN1; SMN2 750/4885KMT2A 1597/4885 |
| US-20070224263-A1 | Aminoalkylphosphonates and related compounds as Edg receptor agonists | ADGRE5, EDNRA, ADGRF1 | TSHR 724/4885SMN1; SMN2 4673/4885KMT2A 3334/4885 |
| US-20140194638-A1 | Spirobenzylamine-Phosphine, Preparation Method Therefor And Use Thereof | FAR1, WEE1, ALDH7A1 | TSHR 1632/4885SMN1; SMN2 4257/4885KMT2A 2333/4885 |
| US-20110118472-A1 | Spiro Phosphine-Oxazoline, Preparation Method and Application thereof | ADH1A, ADH1C, ALDH7A1 | TSHR 2502/4885SMN1; SMN2 3550/4885KMT2A 3058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.